LegoChem Biosciences (LCB), based in Daejeon South Korea, has entered into a research licensing agreement with Takeda Pharmaceuticals Co. to evaluate next-gen antibody drug conjugate (ADC) candidates. Takeda will have access to LCB’s ConjuAll, a next-gen ADC technology platform using a site-specific bio-conjugation method and a stable beta-glucuronide linker to design homogeneous plasma stable ADCs with the potential for improved payload delivery to cancer cells. The companies will focus on e...